Your session is about to expire
← Back to Search
Cadisegliatin: 52 Week Double Blind Treatment Period - 800 mg BID for Type 1 Diabetes (CATT1 Trial)
Phase 3
Waitlist Available
Research Sponsored by vTv Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 26 and 52 weeks
Awards & highlights
Summary
This is a Phase 3 trial of cadisegliatin in participants with Type 1 Diabetes Mellitus.
Eligible Conditions
- Type 1 Diabetes
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 26 and 52 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~26 and 52 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Other study objectives
11-item/Short Form Hypoglycemia Fear Scale
8-item Diabetes Distress Scale (participant and partner or family member)
Change in incidence of Level 2 or Level 3 hypoglycemia
+15 moreTrial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Cadisegliatin: 52 Week Double Blind Treatment Period - 800 mg QDExperimental Treatment1 Intervention
The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 52-week treatment period.
Group II: Cadisegliatin: 52 Week Double Blind Treatment Period - 800 mg BIDExperimental Treatment1 Intervention
The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 52-week treatment period.
Group III: Placebo: 52 Week Double Blind Treatment PeriodPlacebo Group1 Intervention
The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 52-week treatment period.
Find a Location
Who is running the clinical trial?
vTv TherapeuticsLead Sponsor
13 Previous Clinical Trials
2,543 Total Patients Enrolled
Thomas Strack, MDStudy DirectorvTv Therapeutics
Share this study with friends
Copy Link
Messenger